Passa al contenuto
Merck

Vai a

E1383

Etoposide

95.0-105.0% (anhydrous basis), powder, topoisomerase II inhibitor

Sinonimo/i:

4′-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside), VP-16-213

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Voi/SKUDisponibilitàPrezzo
25 mg
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
122,00 €
100 mg
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
325,00 €
250 mg
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
516,00 €

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C29H32O13
Numero CAS:
Peso molecolare:
588.56
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
251-509-1
MDL number:
Assay:
95.0-105.0%
Form:
powder

122,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine personalizzato
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti


Nome del prodotto

Etoposide, synthetic, 95.0-105.0%, powder

biological source

synthetic

Quality Segment

assay

95.0-105.0%

form

powder

color

white to off-white

pKa 

9.8

mp

236-251 °C (lit.)

antibiotic activity spectrum

neoplastics

mode of action

DNA synthesis | interferes, enzyme | inhibits

originator

Teva

SMILES string

COc1cc(cc(OC)c1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)c6cc7OCOc7cc26

InChI

1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1

InChI key

VJJPUSNTGOMMGY-MRVIYFEKSA-N

General description

Etoposide belongs to the class of medications known as topoisomerase II inhibitors. This semi-synthetic compound is derived from Podophyllum peltatum, and Podophyllum emodi. The complex formed between etoposide and topoisomerase II initiates a mutagenic and cell death pathway, demonstrating optimal efficacy in tumor cells with elevated levels of topoisomerase II enzymes. Etoposide is administered as an oral or intravenous chemotherapy agent.
Etoposide is synthesised from podophyllotoxins of plants.

Application

Etoposide has been used:
  • to prepare drug stock solution in dimethyl sulfoxide (DMSO) and also to profile and compare the sensitivity of DT40 mutant cells
  • to incubate cells for cell viability assay
  • to treat neuro-2A cells to induce programmed cell death

Biochem/physiol Actions

Antitumor agent that complexes with topoisomerase II and DNA to enhance double-strand and single-strand cleavage of DNA and reversibly inhibit religation.
Etoposide is an antitumor agent that complexes with topoisomerase II and DNA to enhance double-strand and single-strand cleavage of DNA and reversibly inhibit religation. Blocks the cell cycle in in S-phase and G2-phase of the cell cycle; induces apoptosis in normal and tumor cell lines; inhibits synthesis of the oncoprotein Mdm2 and induces apoptosis in tumor lines that overexpress Mdm2.
Etoposide is used in treating advanced testicular cancer, Kaposi′s sarcoma, non-small cell lung cancer (NSCLC), SCLC (small cell lung cancer) and lymphoma.

Features and Benefits

This compound is a featured product for ADME Tox and Apoptosis research. Discover more featured ADME Tox and Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Teva. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
BP885Y0001365E2600000
Etoposide synthetic, 95.0-105.0%, powder

Sigma-Aldrich

E1383

Etoposide

Etoposide British Pharmacopoeia (BP) Reference Standard

BP885

Etoposide

Etoposide European Pharmacopoeia (EP) Reference Standard

E2600000

Etoposide

description

synthetic, 95.0-105.0%, powder

description

British Pharmacopoeia (BP) Reference Standard

description

European Pharmacopoeia (EP) Reference Standard

description

European Pharmacopoeia (EP) Reference Standard

form

powder

form

solid

form

-

form

-

assay

95.0-105.0%

assay

-

assay

-

assay

-

Quality Level

200

Quality Level

-

Quality Level

-

Quality Level

-

originator

Teva

originator

-

originator

-

originator

-

color

white to off-white

color

-

color

-

color

-

mode of action

enzyme | inhibits, DNA synthesis | interferes

mode of action

-

mode of action

-

mode of action

-


Still not finding the right product?

Explore all of our products under Etoposide


pictograms

Health hazardExclamation mark

signalword

Danger

Classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

ppe

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

flash_point_f

Not applicable

flash_point_c

Not applicable

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 1B - Repr. 2



Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti



Domande

  1. What would be the best option for an in-vivo mouse experiment among the different choices available for Etoposide, based on your experience? Additionally, is there any information on whether the compound is best delivered intraperitoneally (IP) or orally (PO)?

    1 risposta
    1. etoposide product has not been validated for in vivo studies. However, among the options available, E1383 has shown good performance for in vivo studies on mice through intraperitoneal injection.

      For more information on this, refer the following citation: Cancer Res. 2016 Jun 1;76(11):3211-23. doi: 10.1158/0008-5472.CAN-15-0025. Epub 2016 Apr 13. "Radiation Sensitivity in a Preclinical Mouse Model of Medulloblastoma Relies on the Function of the Intrinsic Apoptotic Pathway" PMID: 27197166

      Utile?

Recensioni

Nessuna valutazione

Filtri attivi